Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors.
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Treatment Outcome
L-Lactate Dehydrogenase
Retrospective Studies
Prospective Studies
Neoplasm Recurrence, Local
/ pathology
Head and Neck Neoplasms
/ drug therapy
Lymphocytes
/ pathology
Biomarkers
biomarkers
check point control
head and neck cancer
medical oncology
prognostic factor
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
31
01
2023
received:
18
10
2022
accepted:
03
02
2023
medline:
10
5
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). In this single-institution retrospective cohort study, a dataset of patients with R/M HNSCC treated with ICIs between 08/2012-03/2021 was established, including demographic and clinicopathologic characteristics. Pretreatment PBBMs were collected and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv5, objective response (ORR) by RECIST 1.1, overall survival (OS), and progression-free survival (PFS). Multivariable models for each outcome were created using elastic net variable selection. Our study included 186 patients, with 51 (27%) demonstrating complete or partial response to immunotherapy. Multivariable models adjusted for ECOG performance status (PS), p16, and smoking demonstrated that pretreatment higher LDH and absolute neutrophils, as well as lower percent lymphocytes correlated with worse OS and PFS. Higher LDH and lower % lymphocytes also correlated with worse ORR. In the largest study to date examining PBBMs in ICI-treated R/M HNSCCs, our variable selection method revealed PBBMs prognostic for survival and response to immunotherapy. These biomarkers warrant further investigation in a prospective study along with validation with CPS biomarker.
Sections du résumé
BACKGROUND
Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
METHODS
In this single-institution retrospective cohort study, a dataset of patients with R/M HNSCC treated with ICIs between 08/2012-03/2021 was established, including demographic and clinicopathologic characteristics. Pretreatment PBBMs were collected and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv5, objective response (ORR) by RECIST 1.1, overall survival (OS), and progression-free survival (PFS). Multivariable models for each outcome were created using elastic net variable selection.
RESULTS
Our study included 186 patients, with 51 (27%) demonstrating complete or partial response to immunotherapy. Multivariable models adjusted for ECOG performance status (PS), p16, and smoking demonstrated that pretreatment higher LDH and absolute neutrophils, as well as lower percent lymphocytes correlated with worse OS and PFS. Higher LDH and lower % lymphocytes also correlated with worse ORR.
CONCLUSIONS
In the largest study to date examining PBBMs in ICI-treated R/M HNSCCs, our variable selection method revealed PBBMs prognostic for survival and response to immunotherapy. These biomarkers warrant further investigation in a prospective study along with validation with CPS biomarker.
Identifiants
pubmed: 36806947
doi: 10.1002/cam4.5697
pmc: PMC10166901
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
L-Lactate Dehydrogenase
EC 1.1.1.27
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
9384-9391Subventions
Organisme : NIDCD NIH HHS
ID : T32 DC000018
Pays : United States
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J BUON. 2016 May-Jun;21(3):691-7
pubmed: 27569092
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Med. 2023 Apr;12(8):9384-9391
pubmed: 36806947
Tumour Biol. 2015 May;36(5):3389-97
pubmed: 25527156
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33219093
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
PLoS One. 2018 Oct 25;13(10):e0197743
pubmed: 30359383
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cancers (Basel). 2018 Nov 23;10(12):
pubmed: 30477171
Cancer Control. 2020 Jan-Dec;27(1):1073274820978795
pubmed: 33297727
BMC Cancer. 2018 Apr 4;18(1):383
pubmed: 29618336
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Head Neck. 2021 Oct;43(10):3132-3141
pubmed: 34268826
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Head Neck. 2017 Feb;39(2):219-226
pubmed: 27534525
Lung Cancer (Auckl). 2017 Dec 08;8:249-257
pubmed: 29263709
Endocrinol Metab (Seoul). 2021 Feb;36(1):96-105
pubmed: 33677931
J Immunother Cancer. 2018 Aug 31;6(1):84
pubmed: 30170629
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Sci Rep. 2021 Aug 24;11(1):17117
pubmed: 34429476
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Medicine (Baltimore). 2016 May;95(18):e3539
pubmed: 27149460
Clin Respir J. 2017 Nov;11(6):789-796
pubmed: 26619201
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Eur J Cancer. 2013 Jul;49(10):2356-64
pubmed: 23541571